Private Advisor Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Private Advisor Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Buy	+755	New	+$228K	﹤0.01%	2281
2022 Q3	–	Sell	-1,967	Closed	-$287K	–	1919
2022 Q2	$287K	Sell	1,967 -1,505	-43%	-$214K	﹤0.01%	1670
2022 Q1	$567K	Sell	3,472 -353	-9%	-$53.8K	﹤0.01%	1364
2021 Q4	$649K	Sell	3,825 -1,149	-23%	-$214K	﹤0.01%	1320
2021 Q3	$940K	Buy	4,974 +2,750	+124%	+$516K	0.01%	1241
2021 Q2	$377K	Buy	2,224 +788	+55%	+$115K	﹤0.01%	1531
2021 Q1	$203K	Buy	+1,436	New	+$216K	﹤0.01%	1732
2020 Q3	–	Sell	-693	Closed	-$103K	–	1623
2020 Q2	$103K	Buy	+693	New	+$93.4K	﹤0.01%	1690

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisor Group's ALNY Position: Q2 2026 in Review

Private Advisor Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 755 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #2281 among its holdings. This is a return to the name: Private Advisor Group previously reported a position in ALNY as recently as Q2 2022.

Private Advisor Group first reported a position in ALNY in Q2 2020 and has held it in 8 quarters since. The position peaked at $940K in Q3 2021. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Private Advisor Group held 755 shares of Alnylam Pharmaceuticals worth $227K as of Q2 2026.
Alnylam Pharmaceuticals was a new Private Advisor Group position in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2281 holding.
Private Advisor Group first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
Private Advisor Group's Alnylam Pharmaceuticals position peaked at $940K in Q3 2021.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.